Traws Pharma (DE:0T20)
FRANKFURT:0T20
0T20 Stock Chart & Stats
€6.60
€0.00(0.00%)
At close: 4:00 PM EST
€6.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.40 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.01M
Enterprise Value€10.21M
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.87
Next Earnings
Aug 06, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,150,669
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.89Price Target Upside4.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad-spectrum Antiviral Pipeline & Pandemic-preparedness FocusTraws’ explicit strategic pivot to broad-spectrum antivirals and pandemic preparedness establishes durable market relevance. Partnerships and plans for local manufacturing in Nigeria support regulatory navigation, fast deployment and potential stockpiling contracts, creating long-term commercial and public-health channels beyond single-product risk.
Robust Preclinical Efficacy & Improved Formulation Enabling Monthly DosingDemonstrated multi-species preclinical efficacy and a formulation that boosts exposure ~30% materially strengthen product candidate differentiation. A credible once‑monthly prophylactic profile enhances adherence and commercial appeal, reduces dosing frequency barriers, and supports more efficient clinical trial designs and regulatory positioning over time.
Access To Contingent Capital Via Structured Private FinancingThe structured PIPE with upfront proceeds plus milestone-linked warrants provides a multi-stage capital solution that aligns funding to program progress. This conditional financing extends runway into planned milestones and signals external investor support, offering a durable funding mechanism while management executes trials and regulatory interactions.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the business cannot self-fund development, forcing repeated external raises. Over the medium term this constrains strategic choices, increases dilution risk, and makes long-range planning contingent on successful milestone execution and continued capital access rather than organic cash generation.
Negative Shareholders' Equity (2025)Negative equity reflects accumulated losses and asset adjustments that weaken balance sheet resilience. This structural impairment can hinder financing options, increase cost of capital, complicate counterparty relationships and regulatory filings, and limit the company’s flexibility to absorb future setbacks without significant recapitalization.
FDA IND Clinical Hold For Toxicology ConcernsAn FDA clinical hold on toxicology raises material regulatory and timeline risk for U.S. development; resolving it likely requires additional studies and resubmissions. This creates prolonged uncertainty, potential additional costs, and the risk of divergent regulator decisions that can delay or complicate global development and commercialization plans.
Traws Pharma News
0T20 FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was €6.40 and its highest was €6.60 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is €18.01M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 60 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -€0.46 earnings per share for the quarter, beating the consensus estimate of -€0.486 by €0.026.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.7.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,150,669 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -€0.46 in its last earnings report, beating expectations of -€0.486. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in DE:0T20
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
0T20 Stock 12 Month Forecast
Average Price Target
€6.89
▲(4.41% Upside)
Technical Analysis
Options Prices
Currently, No data available
---